Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ --...
Hence then, the article about lilly s kisunla donanemab receives marketing authorization by european commission for the treatment of early symptomatic alzheimer s disease was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease )
Also on site :
- UN renews Sudan ceasefire appeal over ‘unimaginable suffering’ of civilians
- Central African Republic election: Who’s running and what’s at stake?
- Israeli forces continue ceasefire violations with attacks across Gaza